Assessing Family Risk of Blood Clots in Women Aged 18 to 50 During Hormonal Use

What this Trial Is About

Researchers are investigating the risk factors for venous thromboembolism VTE in young women during hormonal exposure such as estrogen-containing pills or pregnancy. This study compares the prevalence of previous VTE in first-degree relatives of women who experienced VTE during hormonal exposure with that in relatives of women who did not. The aim is to understand how family history and inherited thrombophilia contribute to the risk of VTE in this population. Participants are divided into two groups first-degree relatives of women who had a first episode of VTE while on hormonal exposure case group and first-degree relatives of women with similar hormonal exposure but no VTE history control group. Both groups complete questionnaires, provide blood samples, and may undergo echo-Doppler examinations. The study is cross-sectional and observational, conducted in multiple centers across France. During the study, participants will be assessed for history and symptoms of VTE, with blood tests performed to detect inherited thrombophilia markers such as factor V Leiden and the prothrombin 20210A gene variant. Researchers will measure the presence of symptomatic VTE in first-degree relatives as the primary outcome. Participants provide written consent, and their health information is carefully collected and analyzed to determine familial risk patterns. The study is expected to continue until October 2026.

Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure